Major OTC Acquisitions, Expansion Likely In 2014
This article was originally published in The Tan Sheet
Executive Summary
With major consumer product divisions potentially in play, analysts take a look at possible buyers and sellers in the OTC space. Switches and consumer business expansion plans are also likely to shape 2014.
You may also be interested in...
In Brief: Bayer bonds, Nestle investment, P&G and Abbott earnings, NAD reviews
Bayer targets acquisitions with bond proceeds; Nestle commits $1 bil. to Mexico expansion; P&G health care sales grow 4%; U.S. sales slow Abbott Nutrition; NAD refers Grey Defence to FTC; Rainbow Light pulls anti-aging claims; and medical food warning letter.
In Brief: Bayer bonds, Nestle investment, P&G and Abbott earnings, NAD reviews
Bayer targets acquisitions with bond proceeds; Nestle commits $1 bil. to Mexico expansion; P&G health care sales grow 4%; U.S. sales slow Abbott Nutrition; NAD refers Grey Defence to FTC; Rainbow Light pulls anti-aging claims; and medical food warning letter.
“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts
Merck executives shift their position about the potential divestiture of its non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands including Claritin and Coppertone could grow globally with a new owner.